MOG抗体相关视神经炎免疫抑制治疗的比较分析:队列研究
该双向队列研究纳入121例MOG抗体相关视神经炎(MOG-ON)患者,观察疾病病程并评估传统免疫抑制治疗(IST)的疗效与耐受性。结果显示,未治疗组中位年化复发率(ARR)为0.5,46.0%患者复发;IST超过6个月者ARR从治疗前1.75降至0.00,复发率20.8%。利妥昔单抗(RTX)与吗替麦考酚酯(MMF)复发率无统计学差异,但RTX停药率显著更低(18.2% vs 57.7%,p=0.0017)。
要点
- 未治疗MOG-ON患者中位ARR为0.5,46.0%在随访中复发。
- IST超过6个月者ARR从1.75降至0.00,复发率20.8%。
- RTX与MMF复发率无差异,但RTX停药率显著更低。
核心结论
- MMF和RTX均可能降低MOG-ON患者的疾病活动度,且RTX耐受性优于MMF。
- 单次发作后观察仍是合理选择,因为未治疗患者中不足半数发生复发。
研究设计与样本
- 双向队列研究,纳入2015年1月至2018年12月间121例MOG-ON患者。
- 分析有和无IST患者的临床特征及年化复发率(ARR)。
主要发现
- 发病中位年龄17.5岁,女性与男性比例为1.24。
- 121例中77例复发,61例发病时年龄小于18岁。
- 非IST组63例中位ARR为0.5,中位随访33.5个月时46.0%患者复发。
- IST超过6个月的53例患者ARR从治疗前1.75降至治疗后0.00,中位随访23.8个月时20.8%患者复发。
- RTX组与MMF组复发率无统计学差异,但RTX组停药率显著低于MMF组(18.2% vs 57.7%,p=0.0017)。
关键数值与推荐
- 非IST组中位ARR为0.5,46.0%患者复发(中位随访33.5个月)。
- IST超过6个月组ARR从1.75降至0.00,20.8%患者复发(中位随访23.8个月)。
- RTX组停药率18.2%,MMF组57.7%,差异有统计学意义(p=0.0017)。
临床怎么用
- 对MOG-ON患者,MMF和RTX均可考虑用于降低疾病活动度。
- 选择IST时需权衡耐受性,RTX因停药率更低可能更有优势。
- 单次发作后并非所有患者均需立即启动IST,可结合病情观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The optimal immunosuppressive therapy (IST) in patients with myelin oligodendrocyte glycoprotein antibody-associated optic neuritis (MOG-ON) remains uncertain. This study aimed to observe the disease course of MOG-ON and evaluate the therapeutic efficacy and tolerability of conventional immunosuppressants through Chinese cohort analysis. METHODS: This bidirectional cohort study included 121 patients with MOG-ON between January 2015 and December 2018. The clinical features and annualised relapse rate (ARR) of patients with and without IST were analysed. RESULTS: The median age at onset was 17.5 years, and the sex ratio (F:M) was 1.24. Of 121 patients, 77 patients relapsed and 61 patients were younger than 18 years at disease onset. The overall median ARR of 63 patients in the non-IST group was 0.5, with 46.0% patients showing relapse at a median follow-up of 33.5 months. In the IST group, the ARR decreased from 1.75 pre-IST to 0.00 post-IST in 53 patients who received IST exceeding 6 months, with 20.8% patients showing relapse at a median follow-up of 23.8 months. The relapse rates of patients treated with rituximab (RTX) and mycophenolate mofetil (MMF) were not statistically different, but the rate of discontinuation was significantly lower in the RTX-treated group (18.2% vs 57.7%, p=0.0017). CONCLUSION: This study provides Class III evidence that both MMF and RTX may lower disease activity in patients with MOG-ON, and RTX showed better tolerability than MMF. However, observation after a single attack remains a good option because less than half of patients not on treatment suffered a relapse.
引用
- Xie L, Zhou H, Song H, et al. Comparative analysis of immunosuppressive therapies for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a cohort study. Br J Ophthalmol. 2021. PMID: 33931394. doi:10.1136/bjophthalmol-2020-318769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。